Artelo Biosciences (ARTL) Expected to Announce Earnings on Tuesday

Artelo Biosciences (NASDAQ:ARTL) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 17th. Analysts expect Artelo Biosciences to announce earnings of ($7.02) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Artelo Biosciences (NASDAQ:ARTL) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($6.48) by $5.59.

Artelo Biosciences Trading Up 8.4%

Shares of ARTL stock opened at $2.07 on Tuesday. Artelo Biosciences has a fifty-two week low of $1.91 and a fifty-two week high of $179.19. The business’s 50 day moving average price is $3.80 and its 200-day moving average price is $20.62.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, September 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Artelo Biosciences presently has a consensus rating of “Reduce”.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a biological signaling network involved in areas such as pain, appetite, inflammation and cancer. The company’s programs are designed to address unmet medical needs in oncology and other therapeutic areas.

Artelo’s development pipeline has included ART27.13, a peripherally restricted cannabinoid receptor type 1 agonist being investigated for cancer-related anorexia and cachexia.